These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19850877)

  • 1. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
    Hasumi Y; Baba M; Ajima R; Hasumi H; Valera VA; Klein ME; Haines DC; Merino MJ; Hong SB; Yamaguchi TP; Schmidt LS; Linehan WM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18722-7. PubMed ID: 19850877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
    J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
    Baba M; Hong SB; Sharma N; Warren MB; Nickerson ML; Iwamatsu A; Esposito D; Gillette WK; Hopkins RF; Hartley JL; Furihata M; Oishi S; Zhen W; Burke TR; Linehan WM; Schmidt LS; Zbar B
    Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15552-7. PubMed ID: 17028174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
    PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
    Chen J; Huang D; Rubera I; Futami K; Wang P; Zickert P; Khoo SK; Dykema K; Zhao P; Petillo D; Cao B; Zhang Z; Si S; Schoen SR; Yang XJ; Zhou M; Xiao GQ; Wu G; Nordenskjöld M; Tauc M; Williams BO; Furge KA; Teh BT
    Kidney Int; 2015 Nov; 88(5):1057-69. PubMed ID: 26083655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.
    van Steensel MA; Verstraeten VL; Frank J; Kelleners-Smeets NW; Poblete-Gutiérrez P; Marcus-Soekarman D; Bladergroen RS; Steijlen PM; van Geel M
    J Invest Dermatol; 2007 Mar; 127(3):588-93. PubMed ID: 17124507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report.
    Li J; Liu F; Liu X; Hu Y; Liu Z; Shen Y; Wan J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2319-2325. PubMed ID: 36258004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.
    Hartman TR; Nicolas E; Klein-Szanto A; Al-Saleem T; Cash TP; Simon MC; Henske EP
    Oncogene; 2009 Apr; 28(13):1594-604. PubMed ID: 19234517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Suppressor Folliculin Regulates mTORC1 through Primary Cilia.
    Zhong M; Zhao X; Li J; Yuan W; Yan G; Tong M; Guo S; Zhu Y; Jiang Y; Liu Y; Jiang Y
    J Biol Chem; 2016 May; 291(22):11689-97. PubMed ID: 27072130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Birt-Hogg-Dubé syndrome in an overall view: Focus on the clinicopathological prospects in renal tumors.
    Wu J; Lu J; Wu CL; Lu M
    Semin Diagn Pathol; 2024 May; 41(3):119-124. PubMed ID: 38242750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
    Schmidt LS
    Fam Cancer; 2013 Sep; 12(3):357-64. PubMed ID: 23108783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birt-Hogg-Dubé syndrome: clinicopathologic findings and genetic alterations.
    Adley BP; Smith ND; Nayar R; Yang XJ
    Arch Pathol Lab Med; 2006 Dec; 130(12):1865-70. PubMed ID: 17149965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.